Physician profile
Keith E Krawiec
NPI 1730186545
$16,665.37
in general payments reported to CMS, 2019-2025
49 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,938 · 2020: $782 · 2021: $2,136 · 2022: $4,061 · 2023: $3,419 · 2024: $3,099 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,747.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,110.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,391.11 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $1,146.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,142.54 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,126.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,059.24 | 2019-2022 | |
| Lilly USA, LLC | $818.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $771.38 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $660.80 | 2019-2025 | Entresto, Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.68 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $496.91 | 2022-2024 | Rexulti |
| Medtronic, INC. | $443.41 | 2023-2024 | Synchromedii, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $412.22 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $402.84 | 2023-2025 | Voquezna |
| Exact Sciences Corporation | $357.72 | 2023-2025 | Cologuard Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Krawiec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.